<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ESCITALOPRAM OXALATE</span><br/>(es-ci-tal'o-pram)<br/><span class="topboxtradename">Lexapro<br/></span><b>Classifications:</b> <span class="classification">central nervous system (cns) agent</span>; <span class="classification">psychotherapeutic agent</span>; <span class="classification">selective serotonin-reuptake inhibitor (ssri)</span><br/><b>Prototype: </b>Fluoxetine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>5 mg, 10 mg, 20 mg tablets; 5 mg/5 mL liquid</p>
<h1><a name="action">Actions</a></h1>
<p>Selective serotonin reuptake inhibitor (SSRI) in the CNS. Antidepressant effect is presumed to be linked to its inhibition
         of CNS presynaptic neuronal uptake of serotonin which results in antidepressant activity. Does not produce any sympathomimetic
         response or anticholinergic activity.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Does not inhibit <small>MAOIS</small>. Selective serotonin reuptake inhibition mechanism results in the antidepressant activity of escitalopram.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Depression, generalized anxiety disorder.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Treatment of panic disorders.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to citalopram; concurrent use of <small>MAOIS</small> or use within 14 d of discontinuing <small>MAOIS</small>; pregnancy (category C); volume depleted; lactation; children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Hypersensitivity to other SSRIs; suicidal ideations, depression, mania, hyponatremia, ethanol intoxication, ECT, dehydration,
         renal or hepatic insufficiency; older adults; concurrent use of diuretics, cardiovascular disease (e.g., dysrhythmias, conduction
         defects, myocardial ischemia); history of seizure disorders or suicidal tendencies.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Depression, Generalized Anxiety</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 10 q.d., may increase to 20 mg q.d. if needed after 1 wk<br/><span class="rdage">Geriatric:</span> <span class="rdroute">PO</span> 10 mg q.d.<br/><br/><span class="indicationtitle">Panic Disorder</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 5 q.d., may increase to 20 mg q.d. if needed after 1 wk<br/><br/><span class="indicationtitle">Hepatic Impairment</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 10 q.d.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Do not begin this drug within 14 d of stopping an <small>MAOI</small>.
         </li>
<li>Reduced doses are advised for the older adult and those with hepatic or renal impairment.</li>
<li>Dose increments should be separated by at least 1 wk.</li>
<li>Store at 15°30° C (59°86° F) in tightly closed container and protect from light.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Fatigue, fever, arthralgia, myalgia. <span class="typehead">CV:</span> Palpitation, hypertension. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea,</span> diarrhea, dyspepsia, abdominal pain, dry mouth, vomiting, flatulence, reflux. <span class="typehead">CNS:</span> Dizziness, <span class="speceff-common">insomnia, somnolence,</span> paresthesia, migraine, tremor, vertigo. <span class="typehead">Metabolic:</span> Increased or decreased weight. <span class="typehead">Respiratory:</span> URI, rhinitis, sinusitis. <span class="typehead">Skin:</span> Increased sweating. <span class="typehead">Urogenital:</span> Dysmenorrhea, decreased libido, ejaculation disorder, impotence, menstrual cramps. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead"> Drug:</span> Combination with <span class="classification">maoi</span> could result in hypertensive crisis, hyperthermia, rigidity, myoclonus, autonomic instability; <b>cimetidine</b> may increase escitalopram levels; <b>linezolid</b> may cause serotonin syndrome. <span class="typehead">Herbal:</span>
<b>St. John's wort</b> may cause serotonin syndrome. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed from GI tract. <span class="typehead">Onset:</span> Approximately 1 wk. <span class="typehead">Peak:</span> 3 h. <span class="typehead">Distribution:</span> 80% protein bound; crosses placenta; distributed into breast milk. <span class="typehead">Metabolism:</span> Metabolized in liver by CYP3A4 2C19 and 2D6 enzymes. <span class="typehead">Elimination:</span> 20% excreted in urine, 80% in bile. <span class="typehead">Half-Life:</span> 25 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for therapeutic effectiveness: Indicated by elevation of mood; 14 wk may be needed before improvement is noted.</li>
<li>Closely observe for worsening of depression or emergence of suicidality.</li>
<li>Lab tests: Monitor periodically hepatic functions, CBC, serum sodium, and lithium levels when the two drugs are given concurrently.</li>
<li>Monitor periodically HR and BP, and carefully monitor complete cardiac status in person with known or suspected cardiac disease.</li>
<li>Monitor closely older adult patients for adverse effects, especially with doses &gt;20 mg/d.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not engage in hazardous activities until reaction to this drug is known.</li>
<li>Avoid using alcohol while taking escitalopram.</li>
<li>Inform physician of commonly used OTC drugs as there is potential for drug interactions.</li>
<li>Report distressing adverse effects including any changes in sexual functioning or response.</li>
<li>Periodic ophthalmology exams are advised with long-term treatment.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>